Big Data and Telecom Analytics Market: Business Case, Market Analysis & Forecasts 2014 - 2019 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27726/Big-Data-and-Telecom-Analytics-Market:-Business-Case,-Market-Analysis-&-Forecasts-2014---2019/

Big Data refers to a massive volume of both structured and unstructured data that is so large that it is difficult to process using traditional database and software techniques.  While the presence of such datasets is not something new, the past few years have witnessed immense commercial investments in solutions that address the processing and analysis of Big Data.
 
Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
 
With access to vast amounts of data sets, telecommunications companies are emerging as major proponents of the Big Data movement. Big Data technologies, and in particular their analytics abilities, offer a multitude of benefits to telecom companies including improved subscriber experience, building and maintaining smarter networks, reducing churn, and generation of new revenue streams. 
 
Mind commerce, thus expects the Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
 
This report provides an in-depth assessment of the global Big Data and telecom analytics markets, including a study of the business case, application use cases, vendor landscape, value chain analysis, case studies and a quantitative assessment of the industry from 2013 to 2019.
 
Topics covered in the report include: 
• The Business Case for Big Data:  An assessment of the business case, growth drivers and barriers for Big Data 
• Big Data Technology:  A review of the underlying technologies that resolve big data complexities
• Big Data Use Cases:  A review of investments sectors and specific use cases for the Big Data market  
• The Big Data Value Chain:  An analysis of the value chain of Big Data and the major players involved within it
• Big Data in Telco Analytics:  How telecom can utilize Big Data technology to reduce churn, optimize their networks, reduce risks and create new revenue streams
• Telco Case Studies:  Case Studies of two major wireless telecom capitalizing on Big Data to reduce churn and improve revenue
• Vendor Assessment & Key Player Profiles:  An assessment of the vendor landscape for leading players within the Big Data market
• Market Analysis and Forecasts:  A global and regional assessment of the market size and forecasts for the Big Data market from 2014 to 2019
Key Findings:
• Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
• Mind Commerce has determined that IBM leads the Big Data market in terms of current investments (from a vendor perspective), with estimated revenue for $1.3 Billion in 2012 for its Big Data services, software and hardware sale
• Despite challenges such as the lack of clear big data strategies, security concerns and the need for workforce re-skilling, the growth potential of Big Data is unprecedented. Mind Commerce estimates that global spending on Big Data will grow at a CAGR of 48% between 2014 and 2019. Big Data revenues will reach $135 Billion by the end of 2019
• Big Data technologies, and in particular their analytics abilities offer a multitude of benefits to telecom including improving subscriber experience, building & maintaining smarter networks, reducing churn and even the generation of new revenue streams
• The Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
Target Audience:
• Investment Firms
• Media Companies
• Utilities Companies
• Financial Institutions
• Application Developers
• Government Organizations
• Retail & Hospitality Companies
• Other Vertical Industry Players
• Analytics and Data Reporting Companies
• Healthcare Service Providers & Institutions
• Fixed and Mobile Telecom service providers
• Big Data Technology/Solution (Infrastructure, Software, Service) Vendors

Australia Solar Power Sector Opportunity Analysis - Reports Corner

For complete information about the report, please visit our website


https://www.reportscorner.com/reports/27512/Australia-Solar-Power-Sector-Opportunity-Analysis/



As Australia is moving towards increased solar power generation, the installed capacity of solar modules has shown considerable growth in the recent years. The use of solar energy for power generation had started way back in 1992 in the country with a few pilot projects and an installed capacity of 7.3 MW. With Australia’s power generation dominated by fossil fuels and a lack of clear solar energy policies and growth framework, the installed capacity could not grow more than 2 to 5 MW per year till 2001. Also, this period saw a growth in hydro and wind power production systems indicating the government’s focus on the other known and technologically available sources of clean energy. Post 2001, the installed capacity addition was in the range of 5 to 12 MW till 2007 on a per year basis. It was only in 2007 when solar power production gained weight and the installed capacity started growing by a larger margin. 
The last couple of years (2011 & 2012) have truly been the solar years for Australia with solar announcing its arrival in a grand manner. More than 1.6 GW was added in last two years which have given solar power development the required momentum. This was achieved through a change in policies and a greater shift of focus of the government from other renewable sources to solar energy. Solar PV in Australia is divided into four sub markets namely, Off-grid domestic, off-grid non-domestic, grid-connected distributed and grid-connected centralized. These four sub markets signify the distribution of the installed capacity in the country. 
Solar PV technology is bound to play a larger role in the electricity production sector of Australia which will certainly be augmented by the increasing investments and positively shaping policies. The government is keen on exploiting all its energy sources and solar being one of the most abundant has taken priority over others. The technology is entering its advanced stage and Australia looks set to embrace the solar energy giving it a bigger share in power generation in the coming years.

“Australia Solar Power Sector Opportunity Analysis” discusses following key issues related to solar power development in Australia:
• Australia Power Sector Overview
• Solar Radiation & Potential
• Grid Connected & Off Grid Solar Capacity
• Domestic & Commercial Solar Capacity
• Feed in Tariff Structure by State
• Photovoltaic Module Manufacturing
• Development of Solar Cities
• Regulatory & Policy Initiatives
• Competitive Landscape

Telecom Managed Services: The Market for Machine-to-Machine (M2M) Managed Service Providers - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27725/Telecom-Managed-Services:-The-Market-for-Machine-to-Machine-(M2M)-Managed-Service-Providers/

Overview:

Machine-to-machine (M2M) communications is a technology that is transforming the way that business is conducted, impacting everything from traditional telephony and IT operations to ERP, SCM, public safety, homeland security, and more.  Traditionally the realm of utilities and SCADA systems, M2M is expanding into many new industries, market segments, applications, and use cases.  Several new areas hold great promise including connected vehicles and healthcare.

The M2M ecosystem is complex and includes device manufacturers, wireless service providers, integrators, platform providers and developers.   There are many drivers for managed services within the M2M value chain.  The report evaluates the M2M market, drivers for managed services providers, competitive marketplace, and provides conclusions and recommendations for players within the value chain.

This research is a must-read for anyone within the M2M community including mobile network operators and other service providers, infrastructure providers, managed service providers, and more.

Target Audience:
• Mobile network operators
• Managed services providers
• Systems integration companies
• Application developers and ASP
• Network integration companies
• Network infrastructure providers
• Enterprise companies of all types
• Investment and M&A companies of all types
• M2M equipment and service providers of all types

Machine-to-Machine (M2M) Business Case: Solutions, Business Models, and ROI by Industry Vertical - Reports Corner

For complete information about the report, please visit our website]

https://www.reportscorner.com/reports/27724/Machine-to-Machine-(M2M)-Business-Case:-Solutions,-Business-Models,-and-ROI-by-Industry-Vertical/

Overview:
 
The Machine-to-Machine (M2M) market is seen as the future for wireless revenue growth with various reports touting market size to reach 50 billion connections by 2020. However, the current market is still under 100 million connections.
 
Since M2M is not the only service for telecom carriers, rather it is not their core service; strategies adopted for M2M cannot be studied on stand-alone basis. The strategies have to be evaluated in context with other strategic initiatives taken by the companies. Hence, over-all strategies have also been discussed in this write-up.
 
This research provides analysis of the business case for M2M from the industry vertical or market segment perspective including specific cases within Healthcare, Vending, Petroleum (Oil & Gas and Propane), and Fleet Management.  The report includes business model analysis, technical solution evaluation, and ROI assessment.
 
The expansion of M2M beyond its roots in utilities and manufacturing industries into many different enterprise operations has opened a host of new opportunities across the entire ecosystem.  Furthermore, various enterprise companies in new industries are making plans to leverage M2M in processes that represent a major shift beyond previous implementations.
 
The information in this report is very valuable to industries/segments address as they assess the M2M business case as well as the M2M service providers as they seek to optimize their respective M2M offerings.
 
Target Audience:
• Mobile network operators
• Systems integration companies
• Enterprise companies of all types
• Investment and M&A companies of all types
• M2M equipment and service providers of all types

Next Generation 9-1-1: Providers and Solutions 2013 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27615/Next-Generation-9-1-1:-Providers-and-Solutions-2013/

Next Generation 9-1-1 ( NG9-1-1) is an initiative that targets updating the 9-1-1 emergency service infrastructure in USA and Canada in order to improve public emergency communications services. The Improvement includes adding text messages, images, video and data beside the traditional phone calls for 9-1-1 service. 
 
This report provides information about NG9-1-1 providers. The report presents analysis for each provider including overview, products and services as well as SWOT analysis which introduces strength points, weaknesses, opportunities and threats.
 
Target Audience:
• Managed service providers, service bureau companies
• Public safety organizations and governmental agencies
• VoIP and Internet Infrastructure as a Service (IaaS) companies
• Wireless service providers: cellular network operators, WiMAX and WiFi
• Wireless vendors including hardware, software and service providers

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27617/Obesity-Therapeutics-to-2019---Safety-Concerns-Hinder-Drug-Performance-Despite-Large-Market-Opportunity/

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market.

Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Scope

- The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.
- A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options
- Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period
- Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
- Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
- An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.
- A detailed discussion of the drivers and barriers for this immature market.

Reasons to buy

The report will enhance your decision-making capability by allowing you to - 
- Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
- Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
- Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
- Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals.

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27616/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification,-Increasing-Efficacy,-and-Pipeline-Innovation-Combine-to-Drive-Growth/

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope

- A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.
- In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
- Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
- Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.
- Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.
- Discussion of the drivers and barriers for market growth or decay.

Reasons to buy

- Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
- Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.
- Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. 
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27040/Purified-Terephthalic-Acid-Global-Market-to-2020---Overcapacity-and-Declining-Margins-to-Hinder-Global-Demand-in-the-Short-Term/

Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term

Summary

GBI Research’s "Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term" is an in-depth report focusing on the demand side of the global Purified Terephthalic Acid (PTA) industry. The report provides the reader with detailed analysis and forecasts of the major economic and market trends expected to affect global PTA demand in all major regions of the world. It also provides analysis and description of the major drivers and restraints affecting PTA demand in various regions. Global PTA demand is assessed in terms of end-user segments, price, and competitive landscape, at both the regional and national level.

Scope

- Drivers, restraints and challenges affecting the growth of the PTA market for all the major regions: Asia-Pacific, Europe, North America, the Middle East and Africa, and South and Central America
- Demand and production volume forecasts for the PTA markets of all major countries in the respective regions worldwide
- Demand volume forecasts for the major end-user applications, highlighting trends and volume share analysis for each of these applications in all major countries
- Pricing forecasts and analysis for the major countries and regions
- PTA import and export trends in all the major countries
- Competitive landscape for the PTA market, for major regions and major countries

Reasons to buy

- An understanding of regional PTA market dynamics, through detailed demand and production forecasts, end-use data and competitive landscape analysis
- Detailed analysis at a country level, enabling the buyer to evaluate opportunities in emerging markets and quantify potential returns on investment
- A detailed understanding of the factors that are expected to affect the growth of the PTA market in different regions of the world
- An identification of the most attractive geographical locations, product segments and end-user applications, in order to increase business revenue
- Understanding of market dynamics and pricing differences between countries, which provides an insight into arbitrage opportunities in terms of trade across countries
- The ability to develop custom strategies, based on current and forecast trends in the production and consumption of PTA
- Advanced insight into each of the major markets, through detailed forecasts for demand, production and end-user analysis
- The ability to benchmark different geographies according to previous and forecast growth of demand, production and end-use of PTA
- Gain knowledge regarding the market shares held by each of the major producers in the PTA market in different regions of the world

India Renewable Energy Sector Opportunity Analysis - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27574/India-Renewable-Energy-Sector-Opportunity-Analysis-/

Renewable energy is deemed as the future of energy and India is working in that direction with its various policies. The government has planned a number of projects that would be launched in the next few years and these will enhance India’s renewable energy status. The research and development phase has already passed and the execution of projects is underway. Given the different policies and incentive packages launched by the government to attract investment in the sector, renewable energy in India is bound to grow at an unprecedented pace. The basic infrastructure has been set up that will facilitate the future of renewable energy in the country.
Indian Government gives multiple benefits to renewable energy projects such as no need for industrial clearance, availability of loan, excise duty exemption, custom duty concession, financial support to renewable energy’s R&D projects, income tax holiday, accelerated depreciation, preferential tariffs, interest and capital subsidies, energy buy-back and third party sale and trading. At the same time, the Government is also trying to reduce the capital cost of renewable energy projects so that more and more companies can invest in the sector. To fulfil this aim, Government is trying to adopt latest and suitable technologies in the sector and promote healthy competition among the players.
India is one of the few countries to have set up an independent ministry to overlook the growth of renewable energy. The Ministry of New and Renewable Energy is the authority that launches the various schemes and projects to enunciate the renewable energy growth and to see that the schemes are properly utilized for the benefit of the nation. MNRE has proposed many schemes that will determine the future of renewable energy in India. These projects will establish a proper growth strategy in the future for the exploitation of the huge potential of renewable sources of energy in the country. There is a large amount of renewable energy potential that can be developed with help from the incentive schemes initiated by the ministry.
In FY’2013, around 57% of the total electricity produced used coal as the source of fuel to generate electricity, 17% power was produced by hydro or water based sources, 12% electricity was generated using renewable energy sources and gas contributed 9% to the total power generation. Government has set a target to generate 53,000 MW from renewable energy sources by 2017. To achieve this ambitious target government has introduced several programs such as Generation Based Incentives (GBI), Renewable Energy Certificates, Feed-in-Tariff (FIT) support, solar specific, Renewable Purchase Obligation (RPO), Generation Based Incentives (GBI) and long term PPAs. 

“India Renewable Energy Sector Opportunity Analysis” Report gives detailed overview on the following aspect related to renewable energy sector in India:
• Significance of Renewable Energy for India 
• Renewable Energy Potential & Installed Capacity by Source
• Government Support & Incentive Framework
• Current Scenario of Decentralize/Off Grid Renewable Energy
• Emerging Sources of Renewable Energy: Hydro, Geothermal & Tidal energy.
• Policy & Regulatory Framework
• Jawaharlal Nehru National Solar Mission
• Future Outlook for Renewable Energy 

Social Media, Internet of Things, and the Future of Public Health - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27575/Social-Media,-Internet-of-Things,-and-the-Future-of-Public-Health/


Public health is "the science and art of preventing disease, prolonging life and promoting health through the organized efforts and informed choices of society, organizations, public and private, communities and individuals." It is concerned with threats to health based on population health analysis. This definition highlights the role played by members of the community in improving health and in defining what is socially and publicly acceptable.
 
There are three main features of public health that define the field and also provide a contrast to the related field of medicine. Public health and medicine often have the similar goals of reducing the impact of disease and improving health and quality of life, but there are some notable differences between the two in the methods of reaching these goals. The primary features of public health are a (1) a view that all people should have healthcare access, regardless of social position, (2) a focus on the health of populations rather than individuals, and (3) a focus on prevention.
 
The use of social media in public health is taking shape as Twitter and other forms of social media are leveraged to identify potential outbreaks.  Public health data is rapidly increasing from all sources.  Sensors, formerly found only in hospital ICUs, are now portable and be used at home, and even sometimes while walking.  The potential for persistent public health monitoring may be realized through introduction of machine-to-machine (M2M) communications, embedded computing/wireless, and related technologies.
 
This report evaluates the impact of social media, Big Data and analytics, and the so called "Internet of Things (IoT)" on public healthcare.  The report evaluates specific companies, solutions, and applications.  The report includes analysis of Big Data and its anticipated use in public health.
 
Report Benefits: 
• Identify the tenants of "Public Health 2.0"
• Identify specific companies, solutions, and applications
• Identify the role of Participatory Epidemiology in public health
• Understand the confluence of Infodemiology and Infoveillance
• Understand the role of data-mining, Big Data, and public health
• Understand the role and importance of social media in public health
• Understand the evolution and future direction of healthcare technology
Target Audience:
• Healthcare service providers
• Healthcare insurance providers
• Healthcare technology companies
• Social media and networking companies
• Policy makers, regulatory bodies, and government
• Consultants and systems integrators for healthcare technology
• M2M, Internet of Things (IoT), and general telecommunications companies
• Public health institutions including CDC, NIH, FDA, CMS, NRHA, WHO, and others

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27508/TAK-700---No-competitive-edge-against-Zytiga-Generics;-while-in-early-setting-competition-is-also-heating-up!---In-the-recent-past,-treatment-paradigm-of-metastatic-prostate-cancer-(mPC)-has-witnessed/


TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up!
In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed a paradigm shift due to the launch of various new drugs (Jevtana, Zytiga, Xtandi, Provenge). There are also a number of new candidates in late stage development to hit this market through different pathways. In the pipeline (Table 2), ~4 drugs are in late stage clinical development to compete against both these molecules (TAK-700, TOK-001, ODM-021, ARN-509), in which TAK-700 is the most advanced. TAK-700 is a selective inhibitor of 17, 20 lyase for production of steroidal hormone (Chart 1). By mechanism of action, it is a more specific 17, 20 lyase inhibitor…… Though there is a high chance that Zytiga patent will get extension beyond 2020, TAK-700 profile………….TAK-700 will be the treatment of choice in patients who….. PhIII data of TAK-700 in mCRPC patients is due in 2H 2013. Table 3 highlights the expected key events which have the potential to change the current treatment paradigm of prostate cancer.
TAK-700 vs. Approved anti Androgen therapy (Table 5, 6): How is TAK-700 different from Zytiga (Table1) in its mechanism of Action? Has this differentiation been revealed in reported clinical trial data?.....................................................
Tables Included:
Table 1: Comparison of CY17Inhibitors Pipeline Drugs Acting On Androgen Synthesis
Table 2: Key Candidates Of Anti Androgen Therapy In Prostate Cancer
Table 3: Upcoming Milestones- TAK-700
Table 4: Reported Clinical Data of TAK-700
Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001
Table 6: Clinical Data Comparision- TAK- 700 vs. Xtandi vs. ARN-509 vs ODM-201
Table 7: Prostate cancer –Market dynamics year 2016 and beyond
Table 8: TAK-700- Ongoing Clinical trials